- Salarius Pharmaceuticals Inc at Ladenburg Thalmann Healthcare Conference TranscriptSep 29, 2022
- Q2 2022 Salarius Pharmaceuticals Inc Earnings Call TranscriptAug 08, 2022€35.92 (+6.21%)Earnings
- Q1 2022 Salarius Pharmaceuticals Inc Earnings Call TranscriptMay 12, 2022€47.2 (+31.55%)Earnings
- Q4 2021 Salarius Pharmaceuticals Inc Earnings Call TranscriptMar 10, 2022€70 (+4.17%)Earnings
- Salarius Pharmaceuticals Inc Asset Acquisition Agreement with DeuteRx LLC - M&A Call TranscriptJan 13, 2022
- Q3 2021 Salarius Pharmaceuticals Inc Earnings Call TranscriptNov 04, 2021€144 (+0.70%)Earnings
- Salarius Pharmaceuticals Inc at Benzinga Healthcare Small Cap Conference (Virtual) TranscriptSep 29, 2021
- Q2 2021 Salarius Pharmaceuticals Inc Earnings Call TranscriptAug 05, 2021€136Earnings
- Salarius Pharmaceuticals Inc Virtual KOL & Investor Event Call TranscriptJun 21, 2021
- Q1 2021 Salarius Pharmaceuticals Inc Earnings Call TranscriptMay 12, 2021€194 (+0.52%)Earnings
- Q4 2020 Salarius Pharmaceuticals Inc Earnings Call TranscriptMar 18, 2021€256 (+1.59%)Earnings
- Salarius Pharmaceuticals Inc to Discuss Advancements in the Phase 1/2 Clinical Trial of Seclidemstat Conference Call TranscriptFeb 24, 2021
- Q3 2020 Salarius Pharmaceuticals Inc Earnings Call TranscriptNov 11, 2020€124 (+5.08%)Earnings
- Q2 2020 Salarius Pharmaceuticals Inc Earnings Call TranscriptAug 12, 2020€171 (-11.40%)Earnings
- Q1 2020 Salarius Pharmaceuticals Inc Earnings Call TranscriptMay 14, 2020€152 (+2.01%)Earnings
- Salarius Pharmaceuticals Inc at SNN Network TranscriptNov 20, 2019
Salarius Pharmaceuticals Inc to Discuss Advancements in the Phase 1/2 Clinical Trial of Seclidemstat Conference Call Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the [Status] Clinical Update -- I'm sorry, the Salarius Clinical Update Call.
At this time, all participants are in a listen only mode. After the speakers' presentation, we will have a question-and-answer session. (Operator Instructions).
At this time, I would like to turn the conference over today to Mr. Jason Rando. Please go ahead, sir.
Good morning, everyone, and thank you for joining today's conference call. Earlier this morning Salarius Pharmaceuticals issued a press release announcing the initiation of the expansion phase of its ongoing Phase 1/2 Clinical Trial for Seclidemstat in relapsed and refractory Ewing sarcoma and Ewing-related sarcoma patients. The press release can be found in the news section of the salariuspharma.com.
Before beginning today's call, I would like to make the following statement. Today, we'll be making forward-looking statements about future expectations, plans, events and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)